Mallinckrodt (MNK) Valuation Range, Estimates Cut at Wells Fargo on Methyphenidate ER Issue
Get Alerts MNK Hot Sheet
Rating Summary:
6 Buy, 14 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Wells Fargo analyst David Maris lowered his valuation range on Mallinckrodt plc (NYSE: MNK) from $88-$89 to $83-$84 after the the FDA announced a proposal to withdraw approval of an ANDA for methylphenidate hydrochloride (HCl) extended-release (ER) tablets.
The firm lowered Q4 estimate by $0.04 from $1.90 to $1.86 based on the assumption MNK's generic methylphenidate ER is pulled from the market this quarter. In addition, they reduced 2017 estimate by $0.50 from $8.25 to $7.75.
The firm maintained an Outperform rating.
For an analyst ratings summary and ratings history on Mallinckrodt plc click here. For more ratings news on Mallinckrodt plc click here.
Shares of Mallinckrodt plc closed at $64.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merck (MRK) PT Raised to $143 at Truist Securities
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Wells Fargo, David MarisSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!